Literature DB >> 31888906

Lyme neuroborreliosis presenting as spinal myoclonus.

Xena Li1, Aaron Kirschner1, Mary Metrie1, Mark Loeb2,3.   

Abstract

Early neurological Lyme disease (neuroborreliosis) typically presents with well-recognised neurological syndromes. Spinal myoclonus is however a rare manifestation of neuroborreliosis. We present the case of a man who developed spinal myoclonus 3 weeks after returning from the Czech Republic where he developed erythema migrans on his arm following multiple tick exposures. Spinal fluid analysis showed a pleocytosis and MRI showed enhancement at C5-C6. His serology was positive for IgM antibodies to Borrelia afzelli He was successfully treated with ceftriaxone and doxycycline with improvement of his spinal myoclonus and radiculitis. We conclude that early Lyme neuroborreliosis may present with uncommon neurological manifestations and so a high degree of suspicion is needed. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  infection (neurology); infections; neurology (drugs and medicines)

Mesh:

Substances:

Year:  2019        PMID: 31888906      PMCID: PMC6936517          DOI: 10.1136/bcr-2019-233162

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Lyme neuroborreliosis presenting with propriospinal myoclonus.

Authors:  V de la Sayette; S Schaeffer; C Queruel; F Bertran; G Defer; P Hazera; E Gallet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

2.  Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid.

Authors:  F Strle; E Ruzić-Sabljić; J Cimperman; S Lotric-Furlan; V Maraspin
Journal:  Clin Infect Dis       Date:  2006-08-08       Impact factor: 9.079

3.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.

Authors:  A Mygland; U Ljøstad; V Fingerle; T Rupprecht; E Schmutzhard; I Steiner
Journal:  Eur J Neurol       Date:  2009-11-23       Impact factor: 6.089

Review 5.  Inflammation and central nervous system Lyme disease.

Authors:  Brian A Fallon; Elizabeth S Levin; Pernilla J Schweitzer; David Hardesty
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

Review 6.  Lyme neuroborreliosis.

Authors:  Uwe Koedel; Hans-Walter Pfister
Journal:  Curr Opin Infect Dis       Date:  2017-02       Impact factor: 4.915

Review 7.  Lyme neuroborreliosis-epidemiology, diagnosis and management.

Authors:  Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

Review 8.  Borrelia burgdorferi (Lyme disease).

Authors:  Eugene D Shapiro
Journal:  Pediatr Rev       Date:  2014-12

9.  Six versus two weeks treatment with doxycycline in Lyme neuroborreliosis: the protocol of a multicentre, non-inferiority, double-blinded and randomised controlled trial.

Authors:  Unn Ljøstad; Åse Mygland; Anne Marit Solheim
Journal:  BMJ Open       Date:  2019-06-14       Impact factor: 2.692

10.  Startle myoclonus induced by Lyme neuroborreliosis: a case report.

Authors:  Julia Schoof; Christian Kluge; Hans-Jochen Heinze; Imke Galazky
Journal:  J Med Case Rep       Date:  2013-05-13
  10 in total
  1 in total

Review 1.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.